drugset
drugset / Trial / NCT04161547

Tolerability and Pharmacokinetics of CSPCHA115 Capsules in Chinese Healthy Volunteers

NCT04161547 ↗

Phase 1 Completed 40 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
RandomizedSingle-groupQuadruple-blindTreatment

Summary

A randomized, single-center, double-blind, ascending multiple-dose, placebo-controlled study to evaluate the tolerability and pharmacokinetics of CSPCHA115 capsules in Chinese healthy volunteers.

Timeline

Start
2019-12-12
Primary completion
2020-06-01
Completion
2020-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject CSPCHA115 Unknown 100 mg Oral
Subject CSPCHA115 Unknown 200 mg Oral
Subject CSPCHA115 Unknown 400 mg Oral
Subject CSPCHA115 Unknown 600 mg Oral

Indications

asthma, nasal polyps, and aspirin intolerance